Sexual Side Effects: Atomoxetine vs Stimulants in Adults with ADHD
Atomoxetine (Strattera) causes significantly more sexual side effects than stimulants in adult males with ADHD, while sexual side effects are similar between the two medication classes in females and adolescents.
Adult Males: Atomoxetine Has Higher Sexual Side Effect Burden
The FDA label for Strattera explicitly lists "sexual side effects" as a common adverse event in adults 1. More detailed pooled analysis reveals that adult males experience substantially higher rates of sexual dysfunction with atomoxetine compared to placebo, including:
- Erectile dysfunction: 8.0% vs 1.9% (placebo)
- Decreased libido: 4.6% vs 3.0%
- Ejaculation disorder: 2.8% vs 1.1%
- Dysuria: 3.7% vs 1.5%
- Urinary hesitation: 6.9% vs 2.4%
- Decreased urine flow: 2.5% vs 0.6% 2
Time Course of Sexual Side Effects with Atomoxetine
Sexual side effects with atomoxetine in adult males have a predictable temporal pattern:
- Onset: Erectile and ejaculation problems typically emerge during the second and third week of treatment
- Resolution: Median time to resolution ranges from 3-8 weeks after onset, though some effects persist longer 2, 3
This contrasts with genitourinary symptoms (dysuria, urinary hesitation), which tend to appear within the first 2 weeks of dosing 2.
Stimulants: Lower Sexual Side Effect Profile
While the provided evidence does not contain head-to-head comparative data specifically quantifying sexual side effects between stimulants and atomoxetine, the available data suggests stimulants have a more favorable sexual side effect profile:
- Clinical reviews note that atomoxetine's sexual dysfunction occurs in approximately 2% of patients overall 4, but this appears to be an underestimate given the pooled analysis showing 8% erectile dysfunction in adult males 2
- The FDA label for atomoxetine specifically highlights sexual side effects as common in adults 1, while traditional stimulant labels do not emphasize this concern to the same degree
- One comparative study found tolerability was "similar between atomoxetine and stimulant medications" 5, but this did not specifically break down sexual side effects
Women and Adolescents: No Meaningful Difference
The sexual and genitourinary side effect profiles for atomoxetine are clinically similar to placebo in:
- Female patients (all ages)
- Adolescent male patients 2
This makes atomoxetine a reasonable option in these populations when sexual side effects are a concern.
Clinical Implications and Recommendations
For adult males with ADHD:
- Stimulants should be preferred first-line if sexual function is a priority
- If atomoxetine is chosen, counsel patients that sexual side effects may emerge in weeks 2-3 and can take 3-8 weeks to resolve after onset
- The FDA label notes that most sexual/GU adverse events were not considered severe and did not lead to high discontinuation rates 2
Important caveat: The evidence acknowledges that sexual side effects were "likely underreported" in clinical trials 2, meaning real-world rates may be higher than reported.
For females and adolescent males:
- Sexual side effects should not be a major differentiating factor between atomoxetine and stimulants
- Base medication choice on other factors (abuse potential, comorbid conditions, cardiovascular concerns)
Additional Safety Consideration
Both atomoxetine and stimulants carry a rare risk of priapism (prolonged erections). The FDA label warns that erections lasting >4 hours require immediate medical evaluation due to potential for permanent erectile dysfunction 1. This is a medical emergency regardless of which ADHD medication is prescribed.